Éditeur(s) : HAL CCSD John Libbey Eurotext
Résumé : National audience
The most recent data on prevalence of chronic hepatitis B and C in the French Overseas Territories (FOT) show great variability among these territories with a prevalence rising from 0.46 to 3.4% for HBs Antigen and from 0.02 to 0.67%for anti HCV antibodies. The modes of transmission rely mainly for HBV on sexual or materno-fetal exposure, especially among people from non-French border endemic areas, and for HCV on blood or nosocomial route. Good adhesion of the treating physicians and pediatricians to vaccination has significantly reduced the prevalence of HBV in the ten past years, with an estimated coverage of 75 to 85%depending on the territories. Although there is still a high prevalence of HBV in some FOT, the screening policy and management are based on those carried out inmetropolitan France, which seems insufficient and inadequate to the situation of these territories. Regarding the therapeutic management of HCV, the means attributed to FOT have been identical to those of metropolitan France but the small number of specialist practitioners and remoteness contributed to provision of new molecules later in certain territories. Medical pluridisciplinary sessions have been implemented and based on the universitary or regional hospitals. Copyright © 2017 John Libbey Eurotext.
ISSN: 2115-3310

hal-01485859
https://hal-univ-rennes1.archives-ouvertes.fr/hal-01485859
DOI : 10.1684/hpg.2016.1379

Éditeur(s) : HAL CCSD
Résumé : International audience
Background: Geographical disparities in breast cancer incidence and outcomes are reported worldwide. Women of African descent show lower incidence, higher mortality rates and earlier age of onset. We analyzed data from the cancer registry of Guadeloupe for the period 2008-2013. Methods: We describe breast cancer characteristics by molecular subtype, as well as estimated observed and net survival. We used Cox proportional hazard models to determine associations between cancer subtypes and death rate, adjusted for variables of interest. Results: Overall, 1275 cases were recorded with a mean age at diagnosis of 57(+/- 14) years. World standardized incidence and mortality were respectively 71.9/100,000 and 14.1/100,000 person-years. Age-specific incidence rates were comparable to European and US populations below the age of 45, and higher in Guadeloupean women aged between 45 and 55 years. Overall, 65.1% of patients were hormone receptor (HR)+ and 20.1% were HR-. Triple negative breast cancers (TNBC) accounted for 14% of all cases, and were more frequent in patients under 40 (21.6% vs. 13.4%, p = 0.02). Five-year net survival was 84.9% [81.4-88.6]. It was higher for HR+/Her2+ and HR+/Her2-subtypes, and lower for HR-/Her2+ and TNBC patients. Conclusion: We found high age-specific incidence rates of breast cancer in women aged 45 to 55 years, which warrants further investigation in our population. However, this population of mainly African descent had good overall survival rates, and data according to subtypes are consistent with those reported internationally. These results may suggest that poorer survival in other African descent populations may not be an inherent feature of the disease but may be amenable to improvement. (C) 2017 Elsevier Ltd. All rights reserved.
Cancer Epidemiology

hal-01519252
https://hal-univ-rennes1.archives-ouvertes.fr/hal-01519252
DOI : 10.1016/j.canep.2017.01.004
PUBMED : 28119121